Literature DB >> 35779947

Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine.

Jonathan G Yost1, Hildegard A Wulf1, Caroline A Browne1, Irwin Lucki2.   

Abstract

Commonly used pain therapeutics, such as opioid medications, exert dangerous side effects and lack effectiveness in treating some types of pain. Ketamine is also used to treat pain, but side effects limit its widespread use. (2R,6R)-hydroxynorketamine (HNK) is a ketamine metabolite that potentially shares some beneficial behavioral effects of its parent drug without causing significant side effects. This study compared the profile and potential mechanisms mediating the antinociception activity of ketamine and (2R,6R)-HNK in C57BL/6J mice. Additionally, this study compared the reversal of mechanical allodynia by (2R,6R)-HNK with gabapentin in a model of neuropathic pain. Unlike the near-immediate and short-lived antinociception caused by ketamine, (2R,6R)-HNK produced late-developing antinociception 24 hours following administration. Pharmacological blockade of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors with 2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX) prevented the initiation and expressionof (2R,6R)-HNK antinociception, suggesting the involvement of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor-dependent glutamatergic mechanisms in the pain reduction-like responses. Blockade of opioid receptors with naltrexone partially prevented the antinociceptive effect of ketamine but was ineffective against (2R,6R)-HNK. Furthermore, (2R,6R)-HNK did not produce dystaxia, even when tested at doses five times greater than those needed to produce antinociception, indicating a superior safety profile for (2R,6R)-HNK over ketamine. Additionally, (2R,6R)-HNK reversed mechanical allodynia in a spared nerve injury model of neuropathic pain with similar short-term efficacy to gabapentin (within 4 hours) while outperforming gabapentin 24 hours after administration. These findings support the further study of (2R,6R)-HNK as a potentially valuable agent for treating different types of pain and establish certain advantages of (2R,6R)-HNK treatment over ketamine and gabapentin in corresponding assays for pain. SIGNIFICANCE STATEMENT: The ketamine metabolite (2R,6R)-HNK produced antinociception in male and female mice 24 hours after administration via activation of AMPA receptors. The effects of (2R,6R)-HNK differed in time course and mechanism and presented a better safety profile than ketamine. (2R,6R)-HNK also reversed allodynia in SNI-operated animals within 4 hours of treatment onset, with a duration of effect lasting longer than gabapentin. Taken together, (2R,6R)-HNK demonstrates the potential for development as a non-opioid analgesic drug. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35779947      PMCID: PMC9426759          DOI: 10.1124/jpet.122.001278

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  47 in total

1.  (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.

Authors:  Dylan Chou; Hsien-Yu Peng; Tzer-Bin Lin; Cheng-Yuan Lai; Ming-Chun Hsieh; Yang-Cheng Wen; An-Sheng Lee; Hsueh-Hsiao Wang; Po-Sheng Yang; Gin-Den Chen; Yu-Cheng Ho
Journal:  Neuropharmacology       Date:  2018-06-25       Impact factor: 5.250

2.  Stress induces pain transition by potentiation of AMPA receptor phosphorylation.

Authors:  Changsheng Li; Ya Yang; Sufang Liu; Huaqiang Fang; Yong Zhang; Orion Furmanski; John Skinner; Ying Xing; Roger A Johns; Richard L Huganir; Feng Tao
Journal:  J Neurosci       Date:  2014-10-08       Impact factor: 6.167

3.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

4.  Spared nerve injury: an animal model of persistent peripheral neuropathic pain.

Authors:  Isabelle Decosterd; Clifford J Woolf
Journal:  Pain       Date:  2000-08       Impact factor: 6.961

5.  Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injury.

Authors:  Caroline A Browne; Hildegard A Wulf; Moriah L Jacobson; Mario G Oyola; T John Wu; Irwin Lucki
Journal:  Exp Neurol       Date:  2021-12-28       Impact factor: 5.330

6.  Digigait quantitation of gait dynamics in rat rheumatoid arthritis model.

Authors:  E R Berryman; R L Harris; M Moalli; C M Bagi
Journal:  J Musculoskelet Neuronal Interact       Date:  2009 Apr-Jun       Impact factor: 2.041

7.  Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice.

Authors:  M Irifune; T Shimizu; M Nomoto; T Fukuda
Journal:  Pharmacol Biochem Behav       Date:  1995 Jun-Jul       Impact factor: 3.533

8.  Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis.

Authors:  Shannon D Shields; William A Eckert; Allan I Basbaum
Journal:  J Pain       Date:  2003-10       Impact factor: 5.820

9.  Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies.

Authors:  Fatma Sultan Kilic; Basar Sirmagul; Engin Yildirim; Setenay Oner; Kevser Erol
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

10.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016.

Authors:  James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-14       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.